5 Best Genomics Stocks To Buy Now

Page 5 of 5

1. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Number of Hedge Fund Holders: 62  

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The US Food and Drug Administration recently accepted a Biologics License Application from BioMarin Pharmaceutical for its hemophilia A gene therapy candidate, valoctocogene roxaparvovec. 

On November 29, Jefferies analyst Akash Tewari maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stock and raised the price target to $120 from $100, highlighting that 80 patients in Germany could get on Roctavian once it is available, which would imply sales above what is modelled by the Street for the fourth quarter of 2022 to the second quarter of 2023.

At the end of the third quarter of 2022, 62 hedge funds in the database of Insider Monkey held stakes worth $3.1 billion in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), compared to 59 in the preceding quarter worth $2.9 billion. 

In its Q2 2022 investor letter, Carillon Tower Advisers, an asset management firm, highlighted a few stocks and BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was one of them. Here is what the fund said:

“BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) rose as the company announced a new approval in Japan for its drug to treat achondroplasia (dwarfism), and investors may have become more optimistic regarding its therapy for haemophilia following a positive opinion from European drug regulators. The drug is pending approval and has been delayed by the U.S. Food and Drug Administration to collect more data.”

You can also take a peek at 15 Best Cybersecurity Stocks To Buy and 25 Smartest Countries in the World.

Page 5 of 5